Novel Diagnostic Biomarker for Alzheimer's Disease06770Ultrasensitive CSF assay detects early pre-tangle soluble tau assemblies, enabling earlier Alzheimer’s diagnosis and targeted therapies.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseLead InventorThomas KarikariDepartmentMed-PsychiatryAll Tech InnovatorsEric E. AbrahamsonMilos Dragan Ikonomovic MDThomas K. KarikariDate Submitted2024-06-10
Heterocyclic Compounds for Imaging Aggregated Tau06319New indole-based PET tracers selectively image 4R-tau in PSP/CBD, aiding early non-Alzheimer’s tauopathy diagnosis and therapy monitoring.Technology TypeMedical DeviceTechnology SubtypeDiagnostic ImagingTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseTagsDiagnostic ImagingLife ScienceLead InventorJeffrey StehouwerDepartmentMed-RadiologyAll Tech InnovatorsThomas GrahamRobert H. MachChester A. Mathis Jr., Ph.D.Date Submitted2023-02-28
Novel Biomarker Tools for Tauopathies06769Antibody-based blood tests detect phosphorylated tau, enabling early tauopathy diagnosis and tracking treatment responses.Technology TypeDiagnostic/AssayTechnology SubtypeIn vitro DiagnosticTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseLead InventorThomas KarikariDepartmentMed-PsychiatryAll Tech InnovatorsThomas K. KarikariXuemei ZengDate Submitted2024-06-06
Biased GPCR Ligands as a Therapeutic Intervention Strategy for Alzheimer's Disease06184Biased GPCR ligands selectively block β-arrestin signaling, reduce amyloid pathology, and preserve safety in Alzheimer's models.Technology TypeTherapeutic ModalityTechnology SubtypeDrug Discovery - TargetTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseLead InventorAmantha ThathiahDepartmentMed-NeurobiologyAll Tech InnovatorsYunhong HuangAmantha ThathiahDate Submitted2022-10-05
Optogenetic Induction of Neurodegenerative Disease Pathologies04130Blue-light induced fusion proteins trigger controllable TDP-43/alpha-synuclein/Tau aggregation, modeling neurodegeneration for high-throughput screening.Technology TypeLife Science Research ToolTechnology SubtypeNucleic AcidTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseAmyotrophic lateral sclerosis (ALS)TagsAgingGeneticsPlatform TechnologyLead InventorChristopher DonnellyDepartmentMed-NeurobiologyAll Tech InnovatorsChristopher James DonnellyJacob R. MannDate Submitted2017-01-15
Bait Oligonucleotides to Prevent TDP-43 Associated Neurodegeneration06987Dual-acting RNA chaperones (24–48 nt) prevent and dissolve TDP-43/FUS aggregates, restoring function and reducing neurodegeneration.Technology TypeTherapeutic ModalityTechnology SubtypeGene Therapy - RNATherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseAmyotrophic lateral sclerosis (ALS)Lead InventorChristopher DonnellyDepartmentMed-NeurobiologyAll Tech InnovatorsChristopher James DonnellyJames ShorterTechnology Readiness Level5. Drug candidate createdDate Submitted2024-11-30CollectionsCell & Gene Therapy
Streamlined Resource–Efficient Assay for Amyloid-β06792A streamlined IP-MS assay uses a common buffer to quantify plasma amyloid-β biomarkers, enabling affordable, noninvasive AD monitoring.Technology TypeDiagnostic/AssayTechnology SubtypeBiomarkerTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseTagsIn Vitro DiagnosticLife ScienceLead InventorThomas KarikariDepartmentMed-PsychiatryAll Tech InnovatorsYijun ChenThomas K. KarikariNathan A. YatesDate Submitted2024-07-05
Novel Research Tool to Study TDP-43 Dysfunction06637CUTS-1 RNA biosensor flags TDP-43 dysfunction cells, enabling real-time disease tracking and targeted ALS/FTD/AD therapies.Technology TypeTherapeutic ModalityTechnology SubtypeGene Therapy - RNATherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseLead InventorChristopher DonnellyDepartmentMed-NeurobiologyAll Tech InnovatorsChristopher James DonnellyDate Submitted2024-02-08CollectionsCell & Gene Therapy
Novel Approach to Reverse Cerebral Cortex Decline06081Proteins linked to aging spine loss identified; 10 drugs may protect cognition, slowing dementia by preserving dendritic spines.Technology TypeTherapeutic ModalityTechnology SubtypeDrug Discovery - TargetTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseDementiaTagsAgingDrug RepurposingLead InventorRobert SweetDepartmentMed-PsychiatryAll Tech InnovatorsPeihao FanJoshua Michael KrivinkoMatthew Luke MacDonaldDate Submitted2022-06-30
Integrated 3D Brain Organoids for Modeling the Blood-Brain Barrier and Neurological Disease Mechanisms06972Integrated 3D brain organoids recreate the blood-brain barrier for long-term neurodegenerative/viral research and safer drug screening.Technology TypeLife Science Research ToolTechnology SubtypeCell LineTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseLead InventorVelpandi AyyavooDepartmentGSPH-Infectious Diseases & MicrobiologyAll Tech InnovatorsVelpandi AyyavooRoberta Souza Dos ReisSathish SelvamDate Submitted2024-11-12
HART: Health App Review Tool07091HART tailors health app recommendations for ADRD patients via four-domain assessment, guiding clinicians, patients, and caregivers.Technology TypeDigital HealthTechnology SubtypeHealthcare DeliveryTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseDementiaTagsClinical Decision SupportLife ScienceLead InventorJulie FaietaDepartmentSHRS-Rehab Sci & TechAll Tech InnovatorsYong Kyung ChoiJulie Marie FaietaHaomin HuDate Submitted2025-02-24
OptoTAU: A Novel Tool for Visualizing and Studying TAU06409OptoTAU enables light-controlled visualization of tau behavior in living cells, aiding discovery of modifiers to prevent tau-related dementia. (21 words)Technology TypeLife Science Research ToolTechnology SubtypeProteinTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseDementiaLead InventorAmantha ThathiahDepartmentMed-NeurobiologyAll Tech InnovatorsAmantha ThathiahXin ZhangDate Submitted2023-05-15CollectionsRare Diseases
iAChSnFR-BTX: A Novel Optical Probe to Monitor Neurotransmitter Release06606Novel optical probe iAChSnFR-BTX enables single-vesicle, real-time acetylcholine release imaging via irreversible toxin binding across species.Technology TypeLife Science Research ToolTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseLead InventorStephen MerineyDepartmentNeuroscienceAll Tech InnovatorsYomna BadawiStephen D. MerineyDate Submitted2024-01-09
Novel Treatment for Retinitis Pigmentosa06383Pyrvinium targets NS LLPS to restore proteostasis, preserve retinal structure, and may treat retinitis pigmentosa and proteinopathies.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceOphthalmologyTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseRetinitis pigmentosa (RP)TagsLife ScienceLead InventorBokai ZhuDepartmentMed-MedicineAll Tech InnovatorsYuanyuan ChenWilliam A. DionBokai ZhuDate Submitted2023-04-23
TDP-43 Targeting Antibodies for Diagnosing Neurodegenerative Diseases07105Antibody-based TDP-43 detection enables early, non-invasive diagnosis of AD, ALS, PD, and related neurodegenerative diseases.Technology TypeTherapeutic ModalityTechnology SubtypeAntibody - mAbTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseAmyotrophic lateral sclerosis (ALS)TagsIn Vitro DiagnosticLead InventorThomas KarikariDepartmentMed-PsychiatryAll Tech InnovatorsThomas K. KarikariXuemei ZengDate Submitted2025-03-04
PET Imaging Agents for Aggregated Tau in the Brain06483Novel 4R-tau PET radiotracers: photostable, high affinity to 4R-tau, enabling early PSP/CBD diagnosis and progression tracking.Technology TypeMedical DeviceTechnology SubtypeDiagnostic ImagingTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseProgressive supranuclear palsyOtherLead InventorChester MathisDepartmentMed-RadiologyAll Tech InnovatorsChester A. Mathis Jr., Ph.D.Jeffrey S. StehouwerDate Submitted2023-08-16
AAV-Based Mitochondrial Gene Therapy: A Novel Approach to Slowing Neurodegeneration07363AAV-PHP.eB–delivered TIM coexpression restores neuronal mitochondrial import, slowing Huntington's progression and broadly addressing neurodegeneration.Technology TypeTherapeutic ModalityTechnology SubtypeGene Therapy - AAVTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseHuntington's DiseaseTagsGeneticsRare diseasePlatform TechnologyLead InventorRobert FriedlanderDepartmentMed-Neurological SurgeryAll Tech InnovatorsSergei Victorovich BaranovDiane L. CarlisleRobert Max FriedlanderTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2025-10-06CollectionsCell & Gene Therapy
Novel Salivary Biomarker for Cognitive Impairment07426Saliva-based sTREM2 biomarker enables noninvasive early detection of cognitive impairment and dementia risk.Technology TypeDiagnostic/AssayTechnology SubtypeBiomarkerTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseTagsBiomarkerIn Vitro DiagnosticLife ScienceLead InventorTharick Ali PascoalDepartmentMed-PsychiatryAll Tech InnovatorsTharick Ali PascoalDaniel Robert ClarkDate Submitted2025-12-09
Targeted Nanoparticle Therapy for Brain Repair: Harnessing Memory T Cells for Endogenous Neuroregeneration and Neuroimmune Homeostasis07316Targeted brain nanoparticles reprogram memory T cells to foster neuroprotection, reduce inflammation, and promote endogenous CNS repair.Technology TypeTherapeutic ModalityTechnology SubtypeDrug Discovery - TargetTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseMultiple Sclerosis (MS)TagsAutoimmuneBiomaterialPolymerLead InventorSwaminathan IyerDepartmentMed-PathologyAll Tech InnovatorsSwaminathan Smita IyerTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2025-08-29CollectionsRegenerative Medicine
Optogenetic Control of Membraneless Organelle Formation04307Blue-light–enabled optogenetic induction of membraneless organelles, enabling spatiotemporal control for disease research and drug screening.Technology TypeLife Science Research ToolTechnology SubtypeOther Life Science Research ToolTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseAmyotrophic lateral sclerosis (ALS)Lead InventorChristopher DonnellyDepartmentMed-NeurobiologyAll Tech InnovatorsJoseph Patrick W. ClarkeChristopher James DonnellyDate Submitted2017-06-26
Epidural Spinal Cord Stimulation System for Improving Neurodegenerative Motor Functions06717Indirect sensory-nerve stimulation via epidural spinal cord system may improve breathing, speech, and swallowing in neurodegenerative disease.Technology TypeMedical DeviceTechnology SubtypeTherapeutic Medical DeviceTherapeutic AreasRespiratoryNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseMultiple Sclerosis (MS)Lead InventorDaryl FieldsDepartmentMed-SurgeryAll Tech InnovatorsDaryl FieldsTechnology Readiness Level4. Prototype testing and refinementDate Submitted2024-04-15
Novel Selective NADPH Oxidase 2 Inhibitors03015Selective bridged tetrahydroisoquinolines inhibit Nox2, reducing ROS-driven cardiovascular, cancer, and neurological risks with targeted IC50.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasEndocrinology and Metabolic DiseasesNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseOtherTagsAgingLead InventorPatrick PaganoDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsEugenia Eugenia Cifuentes PaganoPatrick Joseph PaganoErin M. SkodaDate Submitted2013-04-02CollectionsCardiometabolic
Stroke treatment using designer secretomes04846Designer secretomes from young brains boost aged brain recovery after stroke by replacing downregulated immune and repair factors.Technology TypeTherapeutic ModalityTechnology SubtypeProteinTherapeutic AreasNeuroscienceCardiovascularTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseOtherTagsAgingLead InventorJun ChenDepartmentMed-NeurologyAll Tech InnovatorsJun ChenXiaoming HuLawrence Richard WechslerTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2019-01-02CollectionsCardiometabolic
Aerosolized Peptide Inhibitors of NADPH Oxidase for the Treatment of Cardiopulmonary Diseases02241Aerosolized Nox2-specific peptide blocks NADPH oxidase, reducing cardiopulmonary disease progression with targeted, enhanced delivery.Technology TypeTherapeutic ModalityTechnology SubtypeDrug Delivery / FormulationTherapeutic AreasNeuroscienceCardiovascularTherapeutic IndicationsAlzheimer's DiseaseStrokeParkinson's DiseaseLead InventorPatrick PaganoDepartmentMed-Pharmacology and Chemical BiologyAll Tech InnovatorsPatrick Joseph PaganoTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2010-06-03CollectionsCardiometabolic
Novel Treatment for Neurodegenerative Diseases Associated with Protein Polymerization02252FDA-approved therapies promote autophagy to clear protein aggregates in neurodegenerative models, potentially delaying disease progression.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseHuntington's DiseaseTagsDrug RepurposingLead InventorDavid PerlmutterDepartmentSchool of MedicineAll Tech InnovatorsStephen Chongoh PakDavid Hirsch Perlmutter MDGary A. SilvermanTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2010-06-21
Innovative Short-T2 Sodium MRI for Accurate Intracellular Sodium Measurement03055Compact 23Na MRI using short-T2 imaging enables noninvasive intracellular sodium measurement with lower SAR and higher SNR for clinical use.Technology TypeMedical DeviceTechnology SubtypeDiagnostic ImagingTherapeutic AreasNeuroscienceOncologyTherapeutic IndicationsAlzheimer's DiseaseProgressive supranuclear palsyParkinson's DiseaseLead InventorYongxian QianDepartmentMed-RadiologyAll Tech InnovatorsJames Michael MountzAshok PanigrahyYongxian QianDate Submitted2013-05-15
Stapled Acid-Sensitive Endosome Disrupting Alginates03618Acid-responsive alginoketal nanoparticles release divalent cations and cargo in acidic endosomes, enabling targeted cancer and biofilm therapies.Technology TypeTherapeutic ModalityTechnology SubtypeDrug Delivery / FormulationTherapeutic AreasNeuroscienceOncologyTherapeutic IndicationsAlzheimer's DiseaseParkinson's DiseaseSolid tumorLead InventorAbhinav AcharyaDepartmentChem/Petroleum EngineeringAll Tech InnovatorsAbhinav Prakash AcharyaSteven R. LittleDate Submitted2015-05-21
Disrupting Pathological Protein Inclusions with Nucleic Acids04599Nucleic-acid–based approach prevents pathological protein inclusions (e.g., TDP-43) in neurodegenerative diseases, enabling therapeutics.Technology TypeTherapeutic ModalityTechnology SubtypeGene Therapy - DNATherapeutic AreasNeuroscienceTherapeutic IndicationsAlzheimer's DiseaseLead InventorChristopher DonnellyDepartmentMed-NeurobiologyAll Tech InnovatorsChristopher James DonnellyJacob R. MannTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2018-04-23CollectionsCell & Gene Therapy
